ASCEND phase 3 trial open-label extension study results: natalizumab may delay disability progression in secondary progressive multiple sclerosis (SPMS)

Authors
Category Primary study
JournalNeurology
Year 2017
This article has no abstract
Epistemonikos ID: 674a4a253026407e8330fc3a1ef8a4215c9e338b
First added on: Feb 08, 2025